EDSA Edesa Biotech Inc
Company Analysis
Latest News
🟢 Edesa Biotech is trading 5% up in after-hours trading following $25 million offering priced at $5.50
Edesa Biotech is trading at $4.67 (+5.42%) after rebounding in after-hours trading on August 21, 2026, following a sharp regular-session decline and the...
Edesa Biotech's $25 Million Cash Grab Keeps the Lights On, but Can Diluted Shareholders Still Win the Vitiligo Bet?
Shares of Edesa Biotech tumbled 10% to $4.28 after the Toronto-based clinical-stage drugmaker priced a $25 million underwritten public offering — a deal that...
🔴 Edesa Biotech is trading 10.03% down today after pricing a $25 million underwritten offering
Edesa Biotech is trading at $4.28, down 10.03%, after pricing a $25 million underwritten public offering. - Financing includes 3,870,500 shares and up to...
🔴 Edesa Biotech is trading 6.3% down today after pricing $25 million offering
Edesa Biotech is trading at $4.46, down -6.30% after pricing a $25 million underwritten public offering of shares, pre-funded warrants, and accompanying...
🟢 Edesa Biotech is trading 5% up in pre-market after pricing a $25 million underwritten offering
Edesa Biotech is trading at $5.00 (+5.04%) after pricing a $25 million underwritten public offering on August 20, 2026. - The financing includes 3.87 million...
🟢 Edesa Biotech is trading 6.3% up in after-hours trading after pricing a $25 million public offering
Edesa Biotech is trading 6.30% up at $5.06 after pricing a $25 million underwritten public offering on August 20, 2026. - The offering includes 3.87 million...
Edesa Biotech Prices $25 Million Public Offering of Shares and Warrants
Edesa Biotech, Inc. announced the pricing of an underwritten public offering expected to generate approximately $25.0 million in gross proceeds. The company...
🔴 Edesa Biotech is trading 13.04% down today after pricing a $25 million offering
Edesa Biotech is trading 13.04% down now at $5.00 after pricing a $25 million underwritten public offering at $5.50 per share-and-warrant combination, below...
🔴 Edesa Biotech is trading 13.57% down in pre-market after pricing $25 million offering below previous close
Edesa Biotech is trading 13.57% down at $4.97 after pricing an underwritten public offering at $5.50 per share-and-warrant combination, below the previous...
Edesa Biotech Launches Public Offering, Funding Research and Development
Edesa Biotech commenced an underwritten public offering on August 19, 2026. The offering includes common shares, pre-funded warrants, and accompanying common...
🔴 Edesa Biotech is trading 22.26% down in after-hours trading — no clear catalyst identified
Edesa Biotech is trading 22.26% down at $4.47 after falling sharply from its August 19 regular-session close; no reliable company-specific announcement or...
🟢 Edesa Biotech rises 5.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Edesa Biotech is trading 5% up today in pre-market
Edesa Biotech is trading at $6.00 (+5.03%) in the August 19, 2026 pre-market session, with no clear company-specific catalyst identified. - Recent fiscal...
🟢 Edesa Biotech is trading 7.7% up in after-hours trading without a clearly identified catalyst
Edesa Biotech is trading at $6.15, up 7.71% after-hours on August 18, 2026, without a clearly identified company-specific catalyst. - The August 13 earnings...
🟢 Edesa Biotech is trading 10.47% up today after fiscal third-quarter update and EB06 trial progress
Edesa Biotech is trading 10.47% up at $5.91 after investors responded to its August 13 fiscal third-quarter update. - Reported a $5.4 million quarterly net...
🟢 Edesa Biotech is trading 9.44% up today — no new company-specific announcement identified
Edesa Biotech is trading at $5.86 (+9.44%) with no new company-specific announcement dated August 17, 2026 identified. - The latest reported update, on August...
🟢 Edesa Biotech is trading 10% up in after-hours trading after Phase 2 EB06 vitiligo-site activation
Edesa Biotech is trading 10.28% up now at $5.90 in after-hours trading after closing at $5.35 on August 14, 2026, as the clinical milestone appears to outweigh...
🟢 Edesa Biotech is trading 7.48% up in after-hours trading as EB06 vitiligo study nears recruitment
Edesa Biotech is trading at $5.75 (+7.48%) in after-hours trading, despite an earnings miss, as investors may be responding to completed preparations and...
🟢 Edesa Biotech is trading 5.89% up today after EB06 Phase 2 preparations and site activation
Edesa Biotech is trading 5.89% up now at $5.75 after August 13, 2026 fiscal third-quarter results highlighted completed Phase 2 EB06 preparations and initial...
🟢 Edesa Biotech is trading 5% up today in pre-market after fiscal third-quarter report and EB06 site activation
Edesa Biotech is trading 5.16% up at $5.71 after its August 13, 2026 fiscal third-quarter report and EB06 trial progress. - Reported a $5.4 million net loss,...